**Supplementary Table 2. Description of LIRADS**

|  |  |  |
| --- | --- | --- |
| **LR-NC** | Not categorizable | Image omission/degradation |
| **LR-1** | Definitely benign | Definite cyst, hemangioma, perfusion alteration, fat deposition/sparing, hypertrophic pseudomass, focal scar, confluent fibrosis or lesion that demonstrates spontaneous disappearance. |
| **LR-2** | Probably benign | Probable cyst, hemangioma, perfusion alteration, fat deposition/sparing, hypertrophic pseudomass, focal scar, confluent fibrosis or lesion that demonstrates spontaneous disappearance. |
| **LR-3** | Intermediate probability of malignancy | * No major imaging features\* and <20 mm with or without APHE.
* One major imaging feature without APHE and measuring <20 mm.
 |
| **LR-4** | Probably HCC | * No major imaging feature but >20 mm with APHE.
* One major imaging feature and measuring >20 mm without APHE.
* One major imaging feature with APHE measuring <10 mm or between 10-19 mm if that major feature is an enhancing capsule.
* Two or greater major imaging features without APHE and measuring of any size.
* Two or greater major imaging features with APHE, measuring <10 mm
 |
| **LR-5** | Definitely HCC | * One major imaging feature with APHE, measuring 10-19 mm and if that imaging feature is threshold growth or washout.
* One major imaging feature with APHE and measuring >20 mm.
* Two major imaging features with APHE and measuring >10 mm.
 |
| **LR-TIV** | Tumor in vein | Occluded vein with ill-defined walls, restricted diffusion, contiguity with parenchymal mass or heterogeneous enhancement. |
| **LR-M** | Probably or definitely malignant but not necessarily HCC | Eg. Targetoid lesion |

\*Major imaging feature can include enhancing capsule, nonperipheral washout, or threshold growth.

Abbreviations: APHE, arterial phase hyperenhancement; HCC, hepatocellular carcinoma.